Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.73
-0.71 (-10.96%)
At close: Sep 15, 2025, 4:00 PM EDT
5.72
0.00 (-0.09%)
After-hours: Sep 15, 2025, 7:59 PM EDT
Abeona Therapeutics Revenue
Abeona Therapeutics had revenue of $400.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $400.00K.
Revenue (ttm)
$400.00K
Revenue Growth
n/a
P/S Ratio
733.92
Revenue / Employee
$2,941
Employees
136
Market Cap
293.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 3.50M | 2.09M | 147.52% |
| Dec 31, 2022 | 1.41M | -1.59M | -52.87% |
| Dec 31, 2021 | 3.00M | -7.00M | -70.00% |
| Dec 31, 2020 | 10.00M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ABEO News
- 13 days ago - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 27 days ago - Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn - Seeking Alpha
- 4 weeks ago - Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 6 weeks ago - AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients - GlobeNewsWire
- 2 months ago - ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area - GlobeNewsWire
- 2 months ago - Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy - PRNewsWire